Q2 2026 saw 1% net sales growth and flat core operating income, with strong momentum from key brands and new launches offsetting generic erosion. Full-year guidance was reaffirmed, and the pipeline advanced with major regulatory milestones and acquisitions.Original document: Novartis AG [NOVN] Slid…
Q2 2026 saw 1% net sales growth and flat core operating income, with strong momentum from key brands and new launches offsetting generic erosion. Full-year guidance was reaffirmed, and the pipeline advanced with major regulatory milestones and acquisitions.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.